Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Loxo Oncology Inc    LOXO

LOXO ONCOLOGY INC

(LOXO)
My previous session
Most popular
  Report  
 SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
More Financials
Company
Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the... 
More about the company
Latest news on LOXO ONCOLOGY INC
02/23LOXO ONCOLOGY : Bayer to commercialize TRK inhibitor as Roche creates competitio..
AQ
02/19LOXO ONCOLOGY : Bayer takes control of Loxo duo as Lilly closes takeover
AQ
02/19LOXO ONCOLOGY : Lilly closes $8bn Loxo Oncology acquisition
AQ
02/18LOXO ONCOLOGY : Bayer exercised option to obtain full licensing rights for larot..
AQ
02/15LOXO ONCOLOGY, INC. : Completion of Acquisition or Disposition of Assets, Notice..
AQ
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15LOXO ONCOLOGY : Lilly Completes Acquisition of Loxo Oncology
PR
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
02/04ELI LILLY AND : Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting P..
AQ
02/02ELI LILLY AND : Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting P..
AQ
More news
Analyst Recommendations on LOXO ONCOLOGY INC
More recommendations
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart LOXO ONCOLOGY INC
Duration : Period :
Loxo Oncology Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Joshua H. Bilenker President, Chief Executive Officer & Director
Jacob S. van Naarden Chief Operating Officer
Jennifer Burstein Senior Vice President-Finance
S. Michael Rothenberg Vice President-Research & Development
Deborah Morosini VP-Clinical Affairs & Patient Engagement
Sector and Competitors
1st jan.Capitalization (M$)
LOXO ONCOLOGY INC0.00%0
GILEAD SCIENCES3.79%82 398
VERTEX PHARMACEUTICALS10.17%46 013
REGENERON PHARMACEUTICALS7.80%43 537
GENMAB8.52%10 912
SAREPTA THERAPEUTICS INC16.00%9 125